Lorbrexen 100 mg Tablet
Original price was: $550.00.$450.00Current price is: $450.00.
Real world clinical insight
“In the management of ALK-positive non-small cell lung cancer, the central nervous system has historically acted as a sanctuary site. Even when early-generation TKIs effectively controlled systemic disease in the lungs, they often failed to penetrate the blood-brain barrier, leaving the brain vulnerable to metastatic spread. The development of third-generation molecules like Lorlatinib represents a critical shift in our clinical protocols. By effectively crossing the BBB, we can now induce deep intracranial responses and target complex ALK resistance mutations (such as G1202R).
Lorbrexen 100 mg contains the active pharmaceutical ingredient Lorlatinib. It is a potent, third-generation tyrosine kinase inhibitor (TKI) specifically engineered to target the Anaplastic Lymphoma Kinase (ALK) and ROS1 proteins. Lorbrexen is exclusively indicated for the treatment of adult patients with metastatic non- small cell lung cancer (NSCLC) whose tumors are ALK-positive. Designed with high lipophilicity to cross the blood-brain barrier (BBB), Lorlatinib specifically addresses central nervous system (CNS) metastases and overcomes secondary resistance mutations that typically develop after exposure to first- or second- generation ALK inhibitors (such as crizotinib or alectinib).
Reviews
There are no reviews yet.